agencies to monitor the implementation of Presidential Executive Orders.

D. Division of Policy and Planning proposes and implements national policy on the CSE program and provides policy guidance and interpretations to states in developing and operating their programs according to federal law. It develops legislative proposals and regulations to implement new legislation, court decisions or directives from higher authority. The Division develops procedures for review and approval of state plans by the OCSE regional offices. It develops and monitors research, interstate, and other demonstration and evaluation studies and publishes program statistics. The Division is also responsible for strategic planning and performance measurements and standards development. It prepares legislative cost estimates and is responsible for national child support budget formulation.

E. Division of Consumer Services provides direction and leadership for a variety of consumer affairs activities in support of the nationwide child support enforcement program. Provides advice on strategies and approaches to be used to improve public understanding of and access to OCSE programs and policies. Develops and publishes informational materials. Promotes ''best'' child support practices to the public through monthly publication of the *Child Support Report.* Advises the Director and Deputy Director, OCSE of the impact of child support enforcement policy and program upon consumers and provides a focal point for intergovernmental and consumer relations and consultation. The Division is also responsible for operation of the OCSE Homepage on the internet and insuring that the information is placed thereon in a timely manner.

F. Division of State and Local Assistance, in concert with regional offices, provides information and assistance on Child Support Enforcement state operations. It provides national direction and leadership for training and technical assistance activities to increase Child Support Enforcement (CSE) program effectiveness both at Federal and State levels; develops guides and resource materials and serves as a clearinghouse for specialized program techniques for use by ACF regional offices and States; and ensures transfer of best practices among State and local CSE enforcement agencies. The Division, in consultation with the Division of Consumer Services, develops informational materials and operates a national CSE training center; provides logistical support for both training events and meetings; and monitors contracts with organizations affiliated with child support enforcement programs in the areas of training and technical assistance. The Division provides outreach and liaison services to a variety of special interest populations concerning establishment of paternity and collection of child support.

Dated: March 18, 1997.

Olivia A. Golden,

Principal Deputy Assistant Secretary for Children and Families.

[FR Doc. 97–7521 Filed 3–24–97; 8:45 am]

BILLING CODE 4184–01–P

Food and Drug Administration

[Docket No. 91G–0495]

Cerestar USA, Inc., and Roquette America, Inc.; Withdrawal of GRAS Affirmation Petition

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the withdrawal, without prejudice to a future filing, of a petition (GRASP 1G0376) proposing that β-cyclodextrin be affirmed as generally recognized as safe (GRAS) for use as a formulation aid in the production of dry flavoring mixes for preparation of cocktail-type alcoholic beverages.

FOR FURTHER INFORMATION CONTACT: Andrew D. Laumbach, Center for Food Safety and Applied Nutrition (HFS–215), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202–418–3071.

SUPPLEMENTARY INFORMATION: In a notice published in the **Federal Register** of February 3, 1992 (57 FR 4043), FDA announced that a petition (GRASP 1G0376) had been filed by the law offices of Keller and Heckman, 1001 G St. NW., suite 500 West, Washington, DC 20001, on behalf of Cerestar USA, Inc. (formerly, American Maize-Products Co.), 1100 Indianapolis Blvd., Hammond, IN 46320–1094, and Roquette America, Inc. (formerly, Roquette Corp.), 1550 Northwestern Ave., Gurnee, IL 60031–2392. The petition proposed that β-cyclodextrin be affirmed as GRAS for use as a formulation aid in the production of dry flavoring mixes for the preparation of cocktail-type alcoholic beverages.

Recently, the petitioners submitted another petition (GRASP 6G0421) that requests GRAS affirmation of β-cyclodextrin for use as a flavor protectant in human food. The filing of this petition was announced in a notice that published in the **Federal Register** of September 20, 1996 (61 FR 49472). The general use in food that is proposed in petition GRASP 6G0421 encompasses the limited use presently proposed in GRASP 1G0376. Accordingly, the petitioners have requested the withdrawal of GRASP 1G0376. Cerestar USA, Inc., and Roquette America, Inc., have now withdrawn the petition without prejudice to a future filing (21 CFR 171.7).

Dated: February 27, 1997.

Alan M. Rulis,

Director, Office of Premarket Approval, Center for Food Safety and Applied Nutrition.

[FR Doc. 97–7479 Filed 3–24–97; 8:45 am]

BILLING CODE 4160–01–F

[Docket No. 97M–0084]

VISX, Inc.; Premarket Approval of VISX Excimer Laser System (Models B and C) for Photorefractive Keratectomy (PRK)

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing its approval of the application by VISX, Inc., Santa Clara, CA, for premarket approval, under the Federal Food, Drug, and Cosmetic Act (the act), of the VISX Excimer Laser System (Models B and C) for PRK. After reviewing the recommendation of the Ophthalmic Devices Panel, FDA's Center for Devices and Radiological Health (CDRH) notified the applicant, by letter of March 27, 1996, of the approval of the application.

DATES: Petitions for administrative review by April 24, 1997.

ADDRESSES: Written requests for copies of the summary of safety and effectiveness data and petitions for administrative review to the Dockets Management Branch (HFA–305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1–23, Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: Jan C. Callaway, Center for Devices and Radiological Health (HFZ–460), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301–594–2018.

SUPPLEMENTARY INFORMATION: On June 15, 1996, VISX, Inc., Santa Clara, CA 95051, submitted to CDRH an application for premarket approval of the VISX Excimer Laser System (Models B and C). The device is an argon